Numerous landmark clinical trials in people with T2DM have now confirmed the irrefutable benefits of SGLT2 inhibitors for reducing mortality and CV risk as well as preventing both incident or recurrent hospitalisation for heart failure (HHF) and declining renal function [13–21]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.